{"id":"NCT01249872","sponsor":"University of Patras","briefTitle":"Patients-Controlled Epidural Analgesia After Gastric Bypass for Morbid Obesity Using Morphine-Levobupivacaine Regimens","officialTitle":"Postoperative Thoracic Epidural Analgesia in Super Obese Patients (~BMI 60 kg m-2) Undergoing Open Weight Loss Surgery :Does the Addition of Morphine to 0.1% and 0.2% Levobupivacaine Affect Postoperative Pain Relief, Perioperative Lung Function, Return of Normal Gastrointestinal Mobility and Ambulation?","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2010-01","primaryCompletion":"2012-08","completion":"2012-09","firstPosted":"2010-11-30","resultsPosted":"2013-07-24","lastUpdate":"2013-07-24"},"enrollment":96,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Morbid Obesity","Postoperative Pain","Postoperative Bowel Function","Postoperative Ambulation"],"interventions":[{"type":"DRUG","name":"GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE","otherNames":["Morfina cloridrato 10 mg /ml - Morphine","Chirocaine 5 mg/ml - Levobupivacaine"]},{"type":"DRUG","name":"GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE","otherNames":["Morfina cloridrato 10 mg /ml - Morphine","Chirocaine 5 mg/ml - Levobupivacaine"]},{"type":"DRUG","name":"GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE","otherNames":["Morfina cloridrato 10 mg /ml - Morphine","Chirocaine 5 mg/ml - Levobupivacaine"]},{"type":"DRUG","name":"GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE","otherNames":["Morfina cloridrato 10 mg /ml - Morphine","Chirocaine 5 mg/ml - Levobupivacaine"]},{"type":"DRUG","name":"GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE","otherNames":["Morfina cloridrato 10 mg /ml - Morphine","Chirocaine 5 mg/ml - Levobupivacaine"]},{"type":"DRUG","name":"GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE","otherNames":["Morfina cloridrato 10 mg /ml - Morphine","Chirocaine 5 mg/ml - Levobupivacaine"]}],"arms":[{"label":"GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE","type":"ACTIVE_COMPARATOR"},{"label":"GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE","type":"ACTIVE_COMPARATOR"},{"label":"GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE","type":"ACTIVE_COMPARATOR"},{"label":"GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE","type":"ACTIVE_COMPARATOR"},{"label":"GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE","type":"ACTIVE_COMPARATOR"},{"label":"GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE","type":"ACTIVE_COMPARATOR"}],"summary":"Adequate postoperative analgesia can facilitate recovery following gastric bypass surgery for morbid obesity. The efficacy and safety of intravenous patient - controlled analgesia has been studied, but up to date no data are available concerning the use of thoracic epidural patient-controlled analgesia regarding the use of levobupivacaine combined with morphine in morbidly obese patients. The investigators' aim in this prospective, randomized, double-blinded study was to compare the analgesic effectiveness, the dose requirements and side effects of thoracic epidural patient controlled analgesia 0.1% and 0.2% levobupivacaine combined with a continuous epidural administration of morphine, with or without a loading dose, after open gastric bypass for morbid obesity.","primaryOutcome":{"measure":"Change From Baseline in Pain Scores (Visual Analogue Scale)","timeFrame":"up to 48 h postoperatively","effectByArm":[{"arm":"GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE","deltaMin":1.4,"sd":2.3},{"arm":"GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE","deltaMin":1.6,"sd":1.8},{"arm":"GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE","deltaMin":1.6,"sd":2},{"arm":"GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE","deltaMin":0.8,"sd":1.4},{"arm":"GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE","deltaMin":1.1,"sd":1.6},{"arm":"GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE","deltaMin":0.8,"sd":1.2}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":1,"countries":["Greece"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":16},"commonTop":[]}}